RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Voyager Therapeutics Stock

Voyager Therapeutics P/E 2024

Voyager Therapeutics P/E

-4.62

Ticker

VYGR

ISIN

US92915B1061

WKN

A143XJ

As of Jul 13, 2024, Voyager Therapeutics's P/E ratio was -4.62, a -216.67% change from the 3.96 P/E ratio recorded in the previous year.

The Voyager Therapeutics P/E history

Voyager Therapeutics Aktienanalyse

What does Voyager Therapeutics do?

Voyager Therapeutics Inc is a biopharmaceutical company specializing in the development of gene therapy products. The company was founded in 2013 in Cambridge, Massachusetts. The main business model of Voyager Therapeutics involves the development, manufacturing, and marketing of gene therapy products. The company specializes in nervous system and ocular therapies and works closely with leading scientists and clinical institutes. Voyager Therapeutics has several business and research divisions: the Parkinson's Disease division, the Huntington's Disease division, and the Amyotrophic Lateral Sclerosis (ALS) division. The Parkinson's Disease division of Voyager Therapeutics focuses on developing gene therapies for the treatment of Parkinson's disease. The products being developed in this division aim to increase the amount of dopamine in the brain to alleviate the symptoms of Parkinson's disease. Parkinson's patients often suffer from symptoms such as tremors, stiffness, and lack of movement. The Huntington's Disease division of Voyager Therapeutics specializes in developing gene therapy products for the treatment of Huntington's disease. This disease is a hereditary condition that leads to the accumulation of toxic proteins in the brain, eventually causing neurological symptoms such as slow thinking and tremors. The ALS division of Voyager Therapeutics focuses on developing gene therapies for the treatment of Amyotrophic Lateral Sclerosis (ALS). ALS is a neurodegenerative disease in which nerve cells in the brain and spinal cord degenerate, leading to muscle weakness and atrophy. Voyager Therapeutics works closely with various institutions and companies to advance its research and development. Key collaboration partners include Sanofi Genzyme, Abbvie, Neurocrine Biosciences, and the University of Massachusetts Medical School. Some of Voyager Therapeutics' key products are currently in clinical trials or in development. The company is working on developing gene therapies for the treatment of Parkinson's disease, Huntington's disease, and ALS. One example of a product developed by Voyager Therapeutics is VY-AADC, a gene therapy for the treatment of Parkinson's disease. It is currently being tested in Phase 2 clinical trials. Another example is VY-HTT01, a gene therapy for the treatment of Huntington's disease. VY-HTT01 is currently in the preclinical development phase and is expected to be tested in clinical trials in the coming years. Overall, Voyager Therapeutics has a promising future in the gene therapy industry. The company has already achieved significant successes and continues to work intensively on developing new therapies to help people with neurological disorders. Voyager Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Voyager Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Voyager Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Voyager Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Voyager Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Voyager Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Voyager Therapeutics stock

What is the price-to-earnings ratio of Voyager Therapeutics?

The price-earnings ratio of Voyager Therapeutics is currently -4.62.

How has the price-earnings ratio of Voyager Therapeutics changed compared to last year?

The price-to-earnings ratio of Voyager Therapeutics has increased by -216.67% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Voyager Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Voyager Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Voyager Therapeutics affect the company?

An increase in the price-earnings ratio of Voyager Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Voyager Therapeutics affect the company?

A decrease in the price-earnings ratio of Voyager Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Voyager Therapeutics?

Some factors that influence the price-earnings ratio of Voyager Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Voyager Therapeutics pay?

Over the past 12 months, Voyager Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Voyager Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Voyager Therapeutics?

The current dividend yield of Voyager Therapeutics is .

When does Voyager Therapeutics pay dividends?

Voyager Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Voyager Therapeutics?

Voyager Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Voyager Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Voyager Therapeutics located?

Voyager Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Voyager Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Voyager Therapeutics from 7/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/13/2024.

When did Voyager Therapeutics pay the last dividend?

The last dividend was paid out on 7/13/2024.

What was the dividend of Voyager Therapeutics in the year 2023?

In the year 2023, Voyager Therapeutics distributed 0 USD as dividends.

In which currency does Voyager Therapeutics pay out the dividend?

The dividends of Voyager Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Voyager Therapeutics

Our stock analysis for Voyager Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Voyager Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.